CN107677825A - A kind of purposes for the tumor diagnosis composition of diagnosis of cervical cancer and for preparing diagnostic kit - Google Patents
A kind of purposes for the tumor diagnosis composition of diagnosis of cervical cancer and for preparing diagnostic kit Download PDFInfo
- Publication number
- CN107677825A CN107677825A CN201710926283.6A CN201710926283A CN107677825A CN 107677825 A CN107677825 A CN 107677825A CN 201710926283 A CN201710926283 A CN 201710926283A CN 107677825 A CN107677825 A CN 107677825A
- Authority
- CN
- China
- Prior art keywords
- auc
- diagnosis
- cervical cancer
- serum
- acyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
Abstract
A kind of purposes the invention discloses tumor diagnosis composition for diagnosis of cervical cancer and for preparing diagnostic kit.Serum hemolysis phosphatidyl choline (18 is used alone:2), phosphatidylinositols (20:4/0:0) when or the diagnosis of N phenylpropyl alcohol acyl L glutamine distinguishes cervical cancer patient with healthy volunteer, area (AUC) is below 0.7 under ROC curve；Triple combination, which is used to diagnose AUC when distinguishing cervical cancer patient and healthy volunteer, can bring up to 0.945.One skilled in the art will appreciate that area is between 1.0 and 0.5 under ROC curve, in AUC>In the case of 0.5, AUC illustrates that diagnosis effect is better closer to 1.AUC has relatively low accuracy at 0.5 0.7, and AUC has certain accuracy at 0.7 0.9, there is high accuracy when AUC is more than 0.9.Therefore, serum hemolysis phosphatidyl choline (18:2), phosphatidylinositols (20:4/0:0) and N phenylpropyl alcohol acyl L glutamine can combine the diagnostic kit for preparing diagnosing cervical.
Description
Technical field
The invention belongs to medical diagnosis on disease field, it is related to diagnosis marker, and in particular to a kind of for the swollen of diagnosis of cervical cancer
Knurl diagnosis composition and the purposes for preparing diagnostic kit.
Background technology
Cervical carcinoma is one of most common genital tract malignant tumour of women, is in the first place of female reproductive system cancer, closely
Nian Lai, with the increase of the sexually transmitted diseases such as human papillomavirus, the incidence of disease of cervical carcinoma raises year by year, and age of onset becomes
To rejuvenation.Cervical carcinoma early treatment prognosis bona, and late period finds then poor prognosis.Therefore, the early discovery of cervical carcinoma, early diagnosis
Disconnected, early treatment is significant to the survival rate for improving cervical cancer patient.
In recent years, gradually increased to study the report of morbidity and course of disease mechanism with omics technology, including genomics,
MicroRNA groups, protein science, metabolism group etc..Wherein, what metabolism group can be between tracing detection metabolin mutually turns
Change and change with contents level, these information connect with the biochemistry in pathophysiological process and physiological function change can
Using as potential target and action site, and then determine related biomarker.With genomics and protein science etc. other
Omics technology compares, and metabolism group can show its advantage：1. under metabolism group response gene and albumen aspect comprehensive function
Final result, and the faint change of gene and albumen has " multiplier effect " in metabolism group；2. body small molecular compound
Composition it is relatively easy, it is easier to explain its biological function；3. the data analysis of metabolism group can pass through the number such as KEGG or HMDB
Aided according to storehouse.
Metabolic markers are used for noninvasiveization, high efficiency and hommization that diagnosing cervical can realize diagnosis of cervical cancer.
The content of the invention
Diagnosed it is an object of the invention to provide a kind of tumor diagnosis composition for diagnosis of cervical cancer and for preparing
The purposes of kit, to pass through serum can quick diagnosis cervical carcinoma.
The present invention is achieved by following technical scheme：
Lysophosphatidyl choline (18:2), phosphatidylinositols (20:4/0:0) used with N- phenylpropyl alcohols acyl-Glu joint
In the purposes for the diagnosis composition for preparing diagnosing cervical.
Preferably, the lysophosphatidyl choline (18:2), phosphatidylinositols (20:4/0:And N- phenylpropyl alcohol acyl-L- paddy ammonia 0)
Acid amides is serum hemolysis phosphatidyl choline (18:2), serum paraoxonase acyl inositol (20:4/0:And serum N-phenylpropyl alcohol acyl-L- paddy ammonia 0)
Acid amides.
Lysophosphatidyl choline (18:2), phosphatidylinositols (20:4/0:0) used with N- phenylpropyl alcohols acyl-Glu joint
In the purposes for the diagnostic kit for preparing diagnosing cervical.
Preferably, the lysophosphatidyl choline (18:2), phosphatidylinositols (20:4/0:And N- phenylpropyl alcohol acyl-L- paddy ammonia 0)
Acid amides is serum hemolysis phosphatidyl choline (18:2), serum paraoxonase acyl inositol (20:4/0:And serum N-phenylpropyl alcohol acyl-L- paddy ammonia 0)
Acid amides.
Advantages of the present invention：
Serum hemolysis phosphatidyl choline (18 is used alone:2), phosphatidylinositols (20:4/0:Or N- phenylpropyl alcohol acyl-L- paddy 0)
When glutamine diagnosis distinguishes cervical cancer patient with healthy volunteer, area (AUC) is below 0.7 under ROC curve；Triple combination uses
AUC can bring up to 0.945 when diagnosis distinguishes cervical cancer patient with healthy volunteer.One skilled in the art will appreciate that ROC is bent
Area is between 1.0 and 0.5 under line, in AUC>In the case of 0.5, AUC illustrates that diagnosis effect is better closer to 1.AUC exists
There is relatively low accuracy during 0.5-0.7, AUC has certain accuracy in 0.7-0.9, there is high accuracy when AUC is more than 0.9.
Therefore, serum hemolysis phosphatidyl choline (18:2), phosphatidylinositols (20:4/0:0) can join with N- phenylpropyl alcohols acyl-Glu
Share in the diagnostic kit for preparing diagnosing cervical.
Brief description of the drawings
Fig. 1 is serum hemolysis phosphatidyl choline (18:2) it is individually used for distinguishing cervical cancer patient and the ROC of healthy volunteer
Curve；
Fig. 2 is serum paraoxonase acyl inositol (20:4/0:0) it is individually used for distinguishing cervical cancer patient and the ROC of healthy volunteer
Curve；
Fig. 3 is that serum N-phenylpropyl alcohol acyl-Glu is individually used for distinguishing cervical cancer patient and the ROC of healthy volunteer is bent
Line；
Fig. 4 is serum hemolysis phosphatidyl choline (18:2), phosphatidylinositols (20:4/0:And N- phenylpropyl alcohol acyl-L- glutamy 0)
Amine combines the ROC curve for distinguishing cervical cancer patient and healthy volunteer.
Embodiment
Technical scheme is further described with reference to specific embodiment.
First, experiment material
Cervical cancer patient serum specimen is derived from the attached middle large hospital cervical carcinoma postoperative patients of Southeast China University.All patient's arts
It is preceding not receive the treatment such as radiotherapy, chemotherapy and antineoplastic, there is complete clinical and pathological data.Cervical carcinoma
Patient 95 (cervical carcinoma group), age 31-62 year, average age 53.3 years old.
Healthy volunteer's serum specimen 40 (Normal groups), age 32-65 year, average age 54.5 years old.
Age composition no significant difference between cervical carcinoma group and Normal group.
2nd, experimental method
1st, serum sample pre-treatment
200 μ L serum are taken in 1.5mL centrifuge tubes, add 50 μ L 1mg/mL 2- isopropylmalate acid solution internal standards, whirlpool
Rotation mixes for 20 seconds, the mixed solution (ratio 2.5: 1: 1) of 400 μ L methanol, chloroform and water is added, then in 70 DEG C of metal bath
Upper shaking 30min (1200rpm), 16000g × 5min centrifugations (4 DEG C), takes 500 μ L of supernatant in 1.5mL centrifuge tubes, adds 500
μ L distilled water, it is vortexed and mixes, then 16000g × 5min centrifuges (4 DEG C), 500 μ L of supernatant is taken in 1.5mL centrifuge tubes, in room temperature
Lower to be dried up with nitrogen evaporator, the residue obtained methoxamine pyridine solution with 80 μ L dissolves, and the oximate 8h under the conditions of 50 DEG C, adds 60 μ L
N- methyl-N- trimethyl silicon substrate trifluoroacetamides, derivatization 2h, is produced under the conditions of 70 DEG C.
2nd, GC-MS is analyzed
The μ L of sample 2 of above-mentioned derivatization are taken to carry out GC-MS analyses.
Liquid phase chromatogram condition is as follows：Injector temperature：270℃；Sample size：2.0μL；Splitless injecting samples, carrier gas：High-pure helium
(99.999%)；Flow velocity：1.0mL/min；Interface temperature：260℃；Chromatographic column：DB-5MS capillary columns, chromatogram column and programmed temperature
Detected, 80 DEG C of constant temperature 2min, 80 DEG C -300 DEG C (5 DEG C/min) constant temperature 6min.
Mass Spectrometry Conditions are as follows：Ion source temperature：230℃；Level Four bar temperature：150 DEG C, solvent delay：5min；Electron collision
Ionization voltage：70eV, mass spectrum full scan scope (m/z)：30-600, using full scan mode.
Lysophosphatidyl choline (18 is used respectively:2), phosphatidylinositols (20:4/0:Or N- phenylpropyl alcohols acyl-Glu 0)
Chromatographic peak area divided by internal reference 2- isopropylmolic acids peak area, gained ratio is respectively as hemolytic phosphatidyl in each sample
Choline (18:2), phosphatidylinositols (20:4/0:0) or N- phenylpropyl alcohols acyl-Glu relative amount.
3rd, statistical procedures
Analyzed using the softwares of SPSS 20.0, represented with mean value ± deviation, compared between group and examined using t.Evaluation is every
Index application value, draw Receiver Operating Characteristics (ROC) curve, and area (AUC) under calculated curve；It is poor with P ＜ 0.05
It is different statistically significant.The diagnostic value of each single index and Joint Index to cervical carcinoma is evaluated using ROC curve.
3rd, experimental result
1st, between two groups Tumor Marker Levels comparison
Lysophosphatidyl choline (18 in cervical carcinoma group serum:2) relative amount is significantly lower than Normal group, cervical carcinoma
Phosphatidylinositols (20 in group serum:4/0:0), the relative amount of N- phenylpropyl alcohols acyl-Glu is obviously higher than normal control
Group, difference are statistically significant (t values are respectively 1.733,1.479 and 2.314, P ＜ 0.01).Comparative result is as shown in table 1.
The comparison (mean value ± deviation) of Tumor Marker Levels between 1 two groups of table
2nd, tumor-marker analyte detection cervical carcinoma ROC curve is analyzed
Serum hemolysis phosphatidyl choline (18 is used alone:2), phosphatidylinositols (20:4/0:Or N- phenylpropyl alcohol acyl-L- paddy 0)
When glutamine diagnosis distinguishes cervical cancer patient with healthy volunteer, area (AUC) is below 0.7 under ROC curve；Triple combination uses
AUC can bring up to 0.945 when diagnosis distinguishes cervical cancer patient with healthy volunteer.As can be seen here, serum hemolysis phosphatidyl
Choline (18:2), phosphatidylinositols (20:4/0:0) have with N- phenylpropyl alcohols acyl-Glu triple combination for diagnosing cervical
There is higher clinical value.The ROC curve analysis of three indexs combines dualistic logistic regression and operated.
ROC curve analysis result is as shown in table 2 and Fig. 1-4.
2 three serum protein moteblites of table individually and Combining diagnosis value ratio compared with
One skilled in the art will appreciate that area is between 1.0 and 0.5 under ROC curve, in AUC>In the case of 0.5, AUC
Closer to 1, illustrate that diagnosis effect is better.AUC has relatively low accuracy in 0.5-0.7, and AUC fixes in 0.7-0.9
True property, there is high accuracy when AUC is more than 0.9.Therefore, serum hemolysis phosphatidyl choline (18:2), phosphatidylinositols (20:
4/0:0) and N- phenylpropyl alcohols acyl-Glu can combine the diagnostic kit for preparing diagnosing cervical.
Claims (4)
1. lysophosphatidyl choline (18:2), phosphatidylinositols (20:4/0:0) combine and be used for N- phenylpropyl alcohols acyl-Glu
Prepare the purposes of the diagnosis composition of diagnosing cervical.
2. purposes according to claim 1, it is characterised in that：The lysophosphatidyl choline (18:2), phosphatidylinositols
(20:4/0:0) and N- phenylpropyl alcohols acyl-Glu is serum hemolysis phosphatidyl choline (18:2), serum paraoxonase acyl inositol (20:
4/0:And serum N-phenylpropyl alcohol acyl-Glu 0).
3. lysophosphatidyl choline (18:2), phosphatidylinositols (20:4/0:0) combine and be used for N- phenylpropyl alcohols acyl-Glu
Prepare the purposes of the diagnostic kit of diagnosing cervical.
4. purposes according to claim 2, it is characterised in that：The lysophosphatidyl choline (18:2), phosphatidylinositols
(20:4/0:0) and N- phenylpropyl alcohols acyl-Glu is serum hemolysis phosphatidyl choline (18:2), serum paraoxonase acyl inositol (20:
4/0:And serum N-phenylpropyl alcohol acyl-Glu 0).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710926283.6A CN107677825B (en) | 2017-10-06 | 2017-10-06 | A kind of tumor diagnosis composition for diagnosis of cervical cancer and the purposes for being used to prepare diagnostic kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710926283.6A CN107677825B (en) | 2017-10-06 | 2017-10-06 | A kind of tumor diagnosis composition for diagnosis of cervical cancer and the purposes for being used to prepare diagnostic kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107677825A true CN107677825A (en) | 2018-02-09 |
| CN107677825B CN107677825B (en) | 2019-04-23 |
Family
ID=61138065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710926283.6A Active CN107677825B (en) | 2017-10-06 | 2017-10-06 | A kind of tumor diagnosis composition for diagnosis of cervical cancer and the purposes for being used to prepare diagnostic kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107677825B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111662985B (en) * | 2020-07-15 | 2021-05-11 | 天津诺道医学检验中心有限公司 | Application of microRNA combined CEA in preparation of cervical cancer early diagnosis kit |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001036977A2 (en) * | 1999-11-16 | 2001-05-25 | Matritech, Inc. | Identification of disease markers involving mass-based-separation |
| WO2011072130A1 (en) * | 2009-12-10 | 2011-06-16 | Purdue Research Foundation | Methods for diagnosing or monitoring for recurrence of prostate cancer |
| CN102884435A (en) * | 2009-11-27 | 2013-01-16 | 贝克Idi心脏和糖尿病研究院控股有限公司 | Lipid biomarkers for stable and unstable heart disease |
| WO2016041013A1 (en) * | 2014-09-16 | 2016-03-24 | Baker Idi Heart And Diabetes Institute Holdings Limited | Glycerolipids and uses therefor |
| CN105445408A (en) * | 2016-01-25 | 2016-03-30 | 齐炼文 | Metabolite marker for diagnosing and distinguishing coronary atherosclerosis and stable angina pectoris |
| CN105651923A (en) * | 2016-03-02 | 2016-06-08 | 齐炼文 | Metabolic marker for diagnosing and distinguishing unstable angina pectoris and acute myocardial infarction |
-
2017
- 2017-10-06 CN CN201710926283.6A patent/CN107677825B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001036977A2 (en) * | 1999-11-16 | 2001-05-25 | Matritech, Inc. | Identification of disease markers involving mass-based-separation |
| CN102884435A (en) * | 2009-11-27 | 2013-01-16 | 贝克Idi心脏和糖尿病研究院控股有限公司 | Lipid biomarkers for stable and unstable heart disease |
| WO2011072130A1 (en) * | 2009-12-10 | 2011-06-16 | Purdue Research Foundation | Methods for diagnosing or monitoring for recurrence of prostate cancer |
| WO2016041013A1 (en) * | 2014-09-16 | 2016-03-24 | Baker Idi Heart And Diabetes Institute Holdings Limited | Glycerolipids and uses therefor |
| CN105445408A (en) * | 2016-01-25 | 2016-03-30 | 齐炼文 | Metabolite marker for diagnosing and distinguishing coronary atherosclerosis and stable angina pectoris |
| CN105651923A (en) * | 2016-03-02 | 2016-06-08 | 齐炼文 | Metabolic marker for diagnosing and distinguishing unstable angina pectoris and acute myocardial infarction |
Non-Patent Citations (1)
| Title |
|---|
| 陈静 等: "一种基于液相色谱-质谱技术进行血清代谢组学研究的方法：从代谢指纹到潜在标志物", 《中国科学 B辑：化学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111662985B (en) * | 2020-07-15 | 2021-05-11 | 天津诺道医学检验中心有限公司 | Application of microRNA combined CEA in preparation of cervical cancer early diagnosis kit |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107677825B (en) | 2019-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Serum metabolomics for early diagnosis of esophageal squamous cell carcinoma by UHPLC-QTOF/MS | |
| Calderón-Santiago et al. | Human sweat metabolomics for lung cancer screening | |
| Jia et al. | Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer | |
| Zhang et al. | Ultraperformance liquid chromatography–mass spectrometry based comprehensive metabolomics combined with pattern recognition and network analysis methods for characterization of metabolites and metabolic pathways from biological data sets | |
| Chen et al. | Serum 27-nor-5β-cholestane-3, 7, 12, 24, 25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer | |
| AU2006291988B2 (en) | Method for the diagnosis of colorectal cancer and ovarian cancer by the measurement of vitamin E-related metabolites | |
| Fan et al. | Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform | |
| Saigusa et al. | Identification of biomarkers to diagnose diseases and find adverse drug reactions by metabolomics | |
| Tian et al. | Prediction of chemotherapeutic efficacy in non–small cell lung cancer by serum metabolomic profiling | |
| Lin et al. | LC‐MS‐based serum metabolic profiling for genitourinary cancer classification and cancer type‐specific biomarker discovery | |
| Wei et al. | Early breast cancer detection using untargeted and targeted metabolomics | |
| Fahrmann et al. | Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer | |
| CN111562338B (en) | Application of transparent renal cell carcinoma metabolic marker in renal cell carcinoma early screening and diagnosis product | |
| CN105044361A (en) | Diagnosis marker suitable for early-stage esophageal squamous cell cancer diagnosis and screening method of diagnosis marker | |
| CN113960215A (en) | Marker for lung adenocarcinoma diagnosis and application thereof | |
| Oeyen et al. | Determination of variability due to biological and technical variation in urinary extracellular vesicles as a crucial step in biomarker discovery studies | |
| Robu et al. | Mass spectrometry of gangliosides in extracranial tumors: Application to adrenal neuroblastoma | |
| Balluff et al. | Direct molecular tissue analysis by MALDI imaging mass spectrometry in the field of gastrointestinal disease | |
| Bian et al. | In-depth mapping carboxylic acid metabolome reveals the potential biomarkers in colorectal cancer through characteristic fragment ions and metabolic flux | |
| Hassan et al. | Metabolomics driven analysis of obesity-linked colorectal cancer patients via GC-MS and chemometrics: A pilot study | |
| Liu et al. | Quantitative metabolomics for investigating the value of polyamines in the early diagnosis and therapy of colorectal cancer | |
| Anjo et al. | A translational view of cells' secretome analysis-from untargeted proteomics to potential circulating biomarkers | |
| Shahid et al. | Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis | |
| CN104634907A (en) | Application of amino acid molecular combination as stomach cancer marker | |
| CN107677825B (en) | A kind of tumor diagnosis composition for diagnosis of cervical cancer and the purposes for being used to prepare diagnostic kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190318 Address after: 211505 D building, 9 Chuang Chuang Road, Zhongshan science and Technology Park, Liuhe District, Nanjing, Jiangsu. Applicant after: Cui Changyou Address before: 211198 1009 Tianyuan East Road, Gao Xin Garden, Jiangning District, Nanjing, Jiangsu. Applicant before: Nanjing fluoro Biological Detection Technology Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190326 Address after: 301799 Room 1201, Building B10, Venture Capital Base, North Fuyuan Road, Wuqing Development Zone, Tianjin Applicant after: Han's joint (Tianjin) Stem Cell Research Institute Co., Ltd. Address before: 211505 D building, 9 Chuang Chuang Road, Zhongshan science and Technology Park, Liuhe District, Nanjing, Jiangsu. Applicant before: Cui Changyou |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |